StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Atrium Therapeutics's price to book ratio was 0.6× on Nov 11, 2026.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.6×–

More Atrium Therapeutics figures

See a number that looks wrong?